anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ubiquitination plays a pivotal regulatory role in tumor progression. Among the components of the ubiquitin-proteasome system (UPS), ubiquitin-protein ligase E3 has emerged as a key molecule. Nevertheless, the biological functions of E3 ubiquitin ligases and their potential mechanisms orchestrating glycolysis in gastric cancer (GC) remain to be elucidated. In this study, we conducted a comprehensive transcriptomic analysis to identify the core E3 ubiquitin ligases in GC, followed by extensive validation of the expression patterns and clinical significance of Tripartite motif-containing 50 (TRIM50) both in vitro and in vivo. Remarkably, we found that TRIM50 was downregulated in GC tissues, associated with malignant progression and poor patient survival. Functionally, overexpression of TRIM50 suppressed GC cell proliferation and indirectly mitigated the invasion and migration of GC cells by inhibiting the M2 polarization of tumor-associated macrophages (TAMs). Mechanistically, TRIM50 inhibited the glycolytic pathway by ubiquitinating Phosphoglycerate Kinase 1 (PGK1), thereby directly suppressing GC cell proliferation. Simultaneously, the reduction in lactate led to diminished M2 polarization of TAMs, indirectly inhibiting the invasion and migration of GC cells. Notably, the downregulation of TRIM50 in GC was mediated by the METTL3/YTHDF2 axis in an m6A-dependent manner. In our study, we definitively identified TRIM50 as a tumor suppressor gene (TSG) that effectively inhibits glycolysis and the malignant progression of GC by ubiquitinating PGK1, thus offering novel insights and promising targets for the diagnosis and treatment of GC.
BACKGROUND Infective endocarditis (IE) is a severe, life-threatening, and relatively common complication after valve replacement operations, with incidence rates varying between 1.8% and 5.8%, with an in-hospital mortality rate of up to 20%. Common microorganisms are (listed by decreasing incidence) Streptococci, Staphylococcus aureus, Enterococci, bacteria of the HACEK group, and fungi. Treatment of IE is complex, typically involving prolonged courses of antibiotics. However, in cases of aortic prosthetic valve endocarditis, root abscess formation with involvement of the aorto-mitral skeleton is not uncommon and complex surgical intervention is required. One of the notable advancements in surgical management is the use of homografts for aortic root endocarditis. CASE REPORT We report the first case series of 8 patients successfully operated on for prosthetic valve endocarditis with extensive aortic root abscess formation in Greece at Onassis Cardiac Surgery Center with the use of aortic homograft. All cases were redo surgeries and had good outcomes. Interestingly, one of the cases had extensive aortic root involvement with abscess formation extending to the aorto-mitral fibrous skeleton, requiring aortic root replacement with homograft, aorto-mitral skeleton reconstruction with bovine pericardium and mitral valve replacement with a mechanical prosthesis. Two other patients required concomitant coronary bypass grafting of the right coronary artery with reversed saphenous vein grafts. CONCLUSIONS Aortic root replacement with aortic homograft is the preferred choice for prosthetic valve endocarditis with aortic root abscess formation. Despite the technical complexity needed for implantation, this option offers a second chance for survival in patients with this challenging condition.
Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
Introduction: Tumor budding (TB) is considered to be a morphological and prognostic factor relevant to colon cancer (CC). The aim of our study is to assess the TB and to evaluate its relationship to clinicopathological findings within stage II and III CC patients as a single center experience. Materials and methods: A total of 120 CC patients operated between 2018 and 2021 at the University Clinic of Digestive Surgery in Skopje, the Republic of North Macedonia were included in this retrospective, single center study. TB was evaluated by the magnification of 200x along the invasive front of the primary tumor on H&E and CKAE1/AE3 immunohistochemically stained sections. Two grades were used: low grade (TB1, 0-4 TBs) and high-grade, which includes intermediate (TB2, 5-9 TBs) and high grade (TB3 ≥10TBs) of TBs. Results: A statistically significant correlation has been identified between high-grade TB and age (p=0.05) of the patients. There was also a significantly higher occurrence of high-grade TB in patients within stage III CC. Statistically significant correlations were also found in lymph node status (p<0.01), vascular invasion (p<0.05), lymphatic invasion (p<0.01), postoperative relapse (p<0.01), and death (p<0.01). Tumor relapse and death were significantly more frequent in patients with high-grade TB than those with low-grade TB. Patients with registered high-grade TB demonstrated significantly lower relapse-free survival (RFS) and overall survival (OS) rates than patients with low-grade TB over the observation period (RFS: 53.8% vs. 98.5%, p<0.001; OS: 65.4% vs. 97.1%, p<0.001, respectively). Patients with lung and liver postoperative relapses had higher percentage of cases with high-grade TB (94.1%). Conclusion: Our results are highly suggestive that TB should be included as a histological biomarker in the pathology report of patients with stage II and stage III CC, because of its prognostic value.
Exercise is a common trigger of heat-related illness (HRI) events in dogs, accounting for 74% of canine HRI cases treated under primary veterinary care in the United Kingdom. However, few empirical studies have evaluated the effectiveness of differing cooling methods for dogs with exertional hyperthermia or HRI. This study aimed to prospectively evaluate effects of ambient conditions and post-exercise management practices (cooling methods and vehicular confinement) on the post-exercise temperature change of dogs participating in UK canicross events. Canine temperature was recorded at three intervals post-exercise: as close as possible to 0- (immediately post-exercise), 5-, and 15-min post-exercise. Ambient conditions and post-exercise management were recorded for 115 cooling profiles from 52 dogs. In 28/115 (24.4%) profiles, the dog's temperature increased during the first 5-min post-exercise. Overall, 68/115 (59.1%) profiles included passive cooling (stood or walked outside), 35 (30.4%) active cooling (cold-water immersion or application of a cooling coat), and 12 (10.4%) involved no cooling and were immediately housed in vehicles. No dogs developed hypothermia during the study and no adverse effects were observed from any cooling method. In hyperthermic dogs, overall post-exercise body temperature change was significantly negatively associated (i.e. the dogs cooled more) with 0-min post-exercise body temperature (β = -0.93, p < 0.001), and not being housed in a vehicle (β = -0.43, p = 0.013). This study provides evidence cold-water immersion (in water at 0.1-15.0 °C) can be used to effectively and safely cool dogs with exertional hyperthermia. Progressive temperature increases in many dogs - even after exercise has terminated - supports the message to "cool first, transport second" when managing dogs with HRI. When transporting dogs post-exercise or with HRI even after active cooling, care should be taken to cool the vehicle before entry and promote air movement around the dog during transport to facilitate ongoing cooling and prevent worsening of hyperthermia during travel.
PURPOSE:The titled stable composition having an adjusted pH of a system of 1.5-6, properties mild to the skin, suppressing hydrolysis at high temperature, obtained by adding a compound having a specific inductive capacity to a cosmetic composition comprising an amino acid alkyl ester salt as a base. CONSTITUTION:A cosmetic composition comprising an amino acid alkyl ester salt as a base material is blended with 5.0-50.0wt% preferably 20.0-50.0wt% compound having a specific inductive capacity at 25 deg.C of 5.0-40.0, and adjusted to pH of 1.6-6. For example, an inorganic acid such as hydrochloric acid, sulfuric acid, and organic acid such as acetic acid, tartaric acid, etc. is used as the pH adjustor. Isopropyl alcohol, propylene glycol, 1,3-butylene glycol, etc. may be cited as the compound having a specific inductive capacity of 5.0-40.0. Glycinecetyl ester hydrochloride, etc. may be cited as the base material of the cosmetic composition.
Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.
Transdermal therapeutic system comprises: (a) a backing layer; (b) a pressure-sensitive adhesive matrix layer containing the active substance; and (c) a release liner, where active substance is fentanyl or its analogue including alfentanil, carfentanil, lofentanil, remifentanil and trefentanil or their salts. The matrix layer comprises first polyisobutylene and/or second polyisobutylene as pressure-sensitive adhesive polymer. The first polyisobutylene has storage modulus, which is constant at 10-40[deg] C and second polyisobutylene has storage modulus, which decreases continuously at 10-40[deg] C. Transdermal therapeutic system comprises: (a) a backing layer; (b) a pressure-sensitive adhesive matrix layer containing the active substance; and (c) a release liner, where the active substance is fentanyl or its analogue including alfentanil, carfentanil, lofentanil, remifentanil and trefentanil or their salts. The matrix layer comprises first polyisobutylene and/or second polyisobutylene as pressure-sensitive adhesive polymer. The first polyisobutylene has a storage modulus, whose value is substantially constant at the temperature of 10-40[deg] C and the second polyisobutylene has a storage modulus, whose value decreases continuously at the temperature of 10-40[deg] C with increasing temperature. The storage modulus in the linear visco-elastic region at a frequency of 10 rad/second is measured using a rheometer with parallel plate geometry, where the pressure-sensitive adhesive matrix layer contains undissolved active substance in the form of active substance particles. An independent claim is also included for producing the transdermal therapeutic system, comprising dispersing the active substance in the permeation enhancer, distributing the first and second polyisobutylenes in a solvent, homogeneously mixing the two polymer-containing solutions, where the polymer-containing solutions are mixed with the dispersed active substance, and optionally other ingredients until a uniform mass is obtained, applying the resulting mass to the release liner or the backing layer, removing the solvent, laminating the backing layer or the release liner and cutting or punching the transdermal therapeutic system into desired size.
All participants will receive the same online group-based weight loss program, a lifestyle intervention which we have demonstrated to be effective in the past. The 16-session, goal-driven behavioral weight control program offers weekly interactive modules that provide evidence-based health education on caloric balance and physical activity increases, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. The intervention is based on social cognitive theory and uses a self-regulation approach to learning new lifestyle habits that can produce and maintain weight loss. Participants in all study arms will be provided with the same calorie and physical activity goals, and all participants will be asked to self-monitor their dietary intake and physical activity daily using an app on their smart phone. They will also be asked to weigh themselves daily, consistent with research indicating that daily weighing is associated with greater weight loss and participants will be provided with a Bluetooth-enabled "smart scale" that will communicate weight to the password-protected study website (visible to only the participant and study staff). The study website also provides the dynamic programmatic content, real time graphic feedback from self-monitoring (for each individual participant) and a study group discussion board for asynchronous group interactions and social support. The website includes the core aspects of the behavioral program and is to be provided to all participants.
Thrombostasin is an anti-clotting protein found in saliva of  Haematobia irritans . Disclosed herein are studies testing blood uptake of horn flies feeding on cattle which confirm the association of ts genotype with blood uptake of horn flies. Blood uptake volumes of homozygous ts10 horn flies were lower than those of other ts genotypes when fed on control cattle. Cattle vaccinated with recombinant protein isoforms rTS9 or rTB8 resisted horn fly feeding by yielding lower blood volumes compared to flies feeding on control cattle. The impact of vaccination varied by ts genotype of flies. Cattle vaccinated with isoforms rTS9 resisted flies of ts2, ts9, and tb8 genotype. Vaccination with isoforms rTB8 produced resistance to ts8, ts9 and tb8 genotype flies. Horn flies of genotype ts10 were not affected with either TS isoforms and fed well on rTS9 and rTB9 vaccinated as on control-vaccinated cattle.
Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that with an amplification of ERBB2/HER2 will be assigned to this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
PURPOSE: A Zizyphus jujuba seed extract is provided to ensure antibacterial activity and to produce a natural antibacterial agent used in food product and medical field. CONSTITUTION: A Zizyphus jujuba seed extract has antibacterial activity to bacteria or pathogens. The Zizyphus jujuba seed extract is an essential oil or organic solvent extract. The essential oil is obtained by distilling Zizyphus jujuba seeds by steaming and drying extracted essential oil with anhydrous sodium sulfate. The organic solvent extract is obtained by extracting Zizyphus jujuba with methanol, hexane, chloroform, or ethyl acetate. An antibacterial pharmaceutical composition against bacteria or pathogens contains the Zizyphus jujuba seed extract as an active ingredient.
The invention provides a traditional Chinese medicine composition for treating a malignant tumor. The traditional Chinese medicine composition comprises three compositions. A first composition is prepared from the following TCM bulk drugs: gentrin knotweed, ternate buttercup root, cordate houttuynia, Scutellaria barbata, cockroach, pseudobulb of appendiculate Cremastra, rhizoma paridis, safflower, Fructus Gardeniae, chicken's gizzard membrane, amber, clerodendroa cyrtophyllum, scorpion and root of large-flowered skullcap. A second composition is prepared from the following TCM bulk drugs: ternate buttercup root, cordate houttuynia, Scutellaria barbata, heydyotis, clerodendroa cyrtophyllum, pseudostellaria root, white ginseng, scorpion, gastrodia tuber, wolfberry, safflower, curcuma tuber and honeysuckle. A third composition is prepared from the following TCM bulk drugs: balloonflower root, bitter orange fruit, dried orange peel, tangerine flavedo, loquat leaf, bitter apricot kernel, gingko, tendril-leaved fritillary bulb, light yellow Sophora toot, curcuma tuber, anemarrhena, honeysuckle, lily, catechu and root of large-flowered skullcap. The traditional Chinese medicine composition is applicable to patients with cancers, can protect the patients from the pain of surgery, radiotherapy and chemotherapy and has the advantages of reduction in treatment courses and cost.
PURPOSE: A pharmaceutical composition and a health food for preventing or treating inflammatory diseases are provided to suppress lipopolysaccharide-induced NO generation in RAW 264.7 macrophage and beef feet inflammation in a carrageenan-induced mouse, thereby strongly preventing inflammatory diseases and having stability as a natural medicinal material. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains a luteolin-5-O-beta-D-glucopyranoside compound as an active ingredient. The compound is derived from Cirsium maackii MAX. The pharmaceutical composition contains a crude extract or a non-solvent soluble extract of Cirsium maackii MAX as an active ingredient. The extract contains the luteolin-5-O-beta-D-glucopyranoside compound of chemical formula 1. A health food for preventing or treating inflammatory diseases contains the composition.
Alzheimer's disease is characterized by the presence of senile plaques formed from beta amyloid (Aβ), and neurofibrillary tangles (NTFs) formed from paired helical filaments consisting of hyperphosphorylated tau. A number of studies have shown that the NTFs correlate better with the duration and severity of Alzheimer's disease than senile plaques. However, a criticism of the primary etiological role of NTFs in Alzheimer's disease is the absence of variants of kinases or phosphatases associated with Alzheimer's disease. Acid phosphatase, a product of the ACP 1 gene, is a ubiquitous low molecular weight protein tyrosine phosphatase. A common allele, ACP 1*A, is associated with a lower activity of acid phosphatase. It is due to an Arg 105 Gln substitution of the ACP1 locus and detected as a Taq I polymorphism. We report a significant association of the low activity 2 allele with sporadic early onset Alzheimer's disease (EOAD). These findings support the possibility that other variants of kinase and genes may be associated with sporadic Alzheimer's disease.
Individuals with mild traumatic brain injury (mTBI) are at increased risk of dying by suicide compared to those without - both among Veteran and civilian populations. 22% of Veterans with mTBI report struggling with suicidal ideation (SI). Despite this, there are no effective evidence-based treatments for co-occurring mTBI and SI. Deficits in social and occupational functioning, which often follow mTBI, are strongly related to suicidal ideation (SI) and improvements in these areas are known to lessen SI. Thus, improving function for those with mTBI and SI is of great potential significance. The impulsivity that Veterans with mTBI exhibit is referred to as "negative urgency impulsivity". It often involves aggressive and self-harming behaviors, which impede societal re-integration and rehabilitation. Prior studies indicate negative urgency impulsivity is: (1) a common TBI sequela and (2) a risk factor for SI. Previous studies have also indicated individuals with TBI, SI and negative urgency impulsivity had reduced right-sided ventromedial prefrontal cortex (VMPFC) volume compared to Veterans without these conditions. The VMPFC plays a key role in controlling impulsive limbic responses. These findings are consistent with published reports suggesting individuals with reduced VMPFC volume are more likely to (a) have SI and (b) behave impulsively.

Transcranial magnetic stimulation (TMS) holds significant therapeutic promise for post-mTBI SI, impulsivity and functional deficits. TMS induces neuroplasticity, leading to changes that have the potential to improve neurorehabilitation outcomes. TMS is effective for treating post-TBI depression when administered to the dorsolateral prefrontal cortex. Intermittent theta burst stimulation (iTBS) is a "second generation" form of TMS that is delivered more rapidly. It has been proposed that frontal pole TMS could directly strengthen connections throughout the prefrontal cortex, including the VMPFC, thereby dampening limbic system activity. Such a TMS treatment strategy could be used to treat post-mTBI impulsivity and SI, ultimately allowing Veterans to regain functioning. It is not know which Veterans would benefit most from this treatment; examining neural connectivity changes before and after iTBS could determine who would respond to frontal pole iTBS and why.

The investigators will conduct a randomized, double-blinded frontal iTBS pilot clinical trial for Veterans with mTBI, impulsivity and SI. As this is a novel treatment approach for this population, this project will focus on testing the safety, feasibility and tolerability of frontal pole iTBS. To inform future research, this project will determine the preliminary effects of iTBS on functioning, negative urgency impulsivity and SI among the pilot sample. This project will also inform future research by examining the relationships between the functional neural connectivity of the VMPFC to the limbic system and how this is affected by iTBS using resting state functional connectivity (rsFC) neuroimaging data, pre- and post-iTBS.
The objective of this study was to investigate the effect of feeding behavior on feed intake and body weight in growing layers and the underlying mechanisms, thereby providing a scientific foundation for optimal feeding practices in growing layers' management. A total of 144 Hy-line brown growing layers of 10 wk old and similar body weight, were divided into 3 treatment groups with different feeding frequency and equal cumulative daily feeding amount: the once-a-day feeding group (F1) was fed at 9:00 am every day, with feeding amount of 150 g/layer; the twice-a-day feeding group (F2) were fed at 9:00 am and 13:00 pm every day, with each feeding amount of 75 g/layer; the 4 times-a-day feeding group (F4) were fed at 9:00 am, 11:00 am, 13:00 pm, and 15:00 pm every day, with each feeding amount of 37.5 g/layer. Pre-experiment lasted for 1 wk and formal experiment lasted for 8 wk. The results indicated that the daily feed intake and body weight were decreased (P < 0.05) while feed conversion ratio was not affected (P > 0.05) as daily feeding times increased. The glandular stomach proportion was significantly increased in twice-a-day feeding group, while liver proportion and ileum length were significantly increased in 4 times-feeding group (P < 0.05). Additionally, 4 times-feeding daily resulted in a significant elevation of blood glucose levels, which may have suppressed feed intake (P < 0.05). In 4 times-feeding group, the plasma triglyceride levels increased as feeding times, accompanied by a notable up-regulation in the mRNA level of appetite-suppressing gene, hypothalamic pro-opiomelanocortin (POMC) and glandular stomach ghrelin. This modulation effectively suppressed the subsequent feed intake and body weight. Therefore, 4 times feeding daily is recommended in growing layers' management, because it reduced the feed cost without affecting the feed conversion efficiency.